JP2024520497A5 - - Google Patents

Info

Publication number
JP2024520497A5
JP2024520497A5 JP2023573141A JP2023573141A JP2024520497A5 JP 2024520497 A5 JP2024520497 A5 JP 2024520497A5 JP 2023573141 A JP2023573141 A JP 2023573141A JP 2023573141 A JP2023573141 A JP 2023573141A JP 2024520497 A5 JP2024520497 A5 JP 2024520497A5
Authority
JP
Japan
Prior art keywords
complement
biomarker
creatinine
sc5b9
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031062 external-priority patent/WO2022251446A1/en
Publication of JP2024520497A publication Critical patent/JP2024520497A/ja
Publication of JP2024520497A5 publication Critical patent/JP2024520497A5/ja
Pending legal-status Critical Current

Links

JP2023573141A 2021-05-28 2022-05-26 Cm-tmaバイオマーカーを検出するための方法 Pending JP2024520497A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194704P 2021-05-28 2021-05-28
US63/194,704 2021-05-28
US202163272033P 2021-10-26 2021-10-26
US63/272,033 2021-10-26
PCT/US2022/031062 WO2022251446A1 (en) 2021-05-28 2022-05-26 Methods for detecting cm-tma biomarkers

Publications (2)

Publication Number Publication Date
JP2024520497A JP2024520497A (ja) 2024-05-24
JP2024520497A5 true JP2024520497A5 (https=) 2025-05-22

Family

ID=82214465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573141A Pending JP2024520497A (ja) 2021-05-28 2022-05-26 Cm-tmaバイオマーカーを検出するための方法

Country Status (5)

Country Link
US (1) US20250199013A1 (https=)
EP (1) EP4348263A1 (https=)
JP (1) JP2024520497A (https=)
CA (1) CA3220629A1 (https=)
WO (1) WO2022251446A1 (https=)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
SI3011345T1 (sl) * 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
WO2019227102A1 (en) * 2018-05-25 2019-11-28 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers

Similar Documents

Publication Publication Date Title
US20240280591A1 (en) Blood-based assay for detecting tauopathy or amyloidogenic disease
JP7586984B2 (ja) Il-33を定量するための方法
JP2013527444A (ja) 抗体を検出するための方法
RU2016135417A (ru) Новый анализ для детектирования периостина человека
CN119731536A (zh) 针对用于治疗tau蛋白病或淀粉样变性疾病的临床试验对受试者进行的基于血液的筛选
JP2024520497A5 (https=)
EP2924437B1 (en) Method for detecting neurological disease accompanied by inflammation and/or demyelination
CN110320367A (zh) 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
CN105980857B (zh) 用于心脏病症的生物标记物
WO2022074648A1 (en) Marker for response to pd-1/pd-l1 immunotherapy
Soosaipillai et al. Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study
CN111323597A (zh) 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法
JP2021032596A (ja) 動脈硬化マーカー及びその利用
US20260092934A1 (en) Kawasaki disease determination kit and kawasaki disease determination method
US20250012795A1 (en) Diagnosing multiple sclerosis (ms)
WO2013086637A1 (en) Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes
EA049359B1 (ru) Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания
Meier Towards Development of Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Precision Medicine Biomarkers for Multiple Sclerosis
HK40096066A (zh) 用於检测tau蛋白病或淀粉样蛋白形成性疾病的基於血液的测定
EA044802B1 (ru) Способы и композиции для количественного определения il-33
HK1229884B (zh) 用於心脏病症的生物标记物